Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kawasaki
Clinical trial register · Japan

Clinical Trials in Kawasaki, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2504 matching records held by the registry are in this view. Synced 31 Oct 2026, 03:19 UTC
2504
Studies in scope
all four open statuses
1278
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 517 Sapporo 398 Tokyo 370 Osaka 353
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC14 Eli Lilly and Company9 Bristol-Myers Squibb6 Novartis Pharmaceuticals5 Pfizer4
Site location
Fukuoka557 Nagoya517 Sapporo398 Tokyo370 Osaka353
All 926 locations
Target enrolment
to

Trials with a site in Kawasaki

85 of 2504 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Eli Lilly and Company
Phase 3
2,115
Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe
2026-12
Not yet open
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
NCT07753005Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage
Aesculap AG
Observational
176
Nagoya, Toyoake, Kashiwa, Gifu, Sapporo, Nishinomiya, Kawasaki, Kashihara
2026-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Fukuoka, Hakata-Ku, Hino, Karatsu, Kawasaki, Kitakyushu, Koshigaya, Kōtō City
2026-08-14
Recruiting
Janssen Research & Development, LLC
Phase 3
348
Kawasaki, Kobe, Kodaira-shi, Maebashi, Minatoku, Mitaka, Nagasaki, Sapporo
2026-07-23
Recruiting
National Cancer Center, Japan
Phase 2
136
Chiba, Fukuoka, Gifu, Maebashi, Hiroshima, Kawasaki, Yokohama, Ina
2026-07-15
Recruiting
argenx
Phase 3
230
Okayama, Bunkyō-Ku, Ōta-ku, Iizuka, Kawasaki, Kitakyushu, Kyoto, Nagasaki
2026-06-10
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki
2026-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tōon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Kawasaki, Miyazaki
2026-03-26
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
NCT07347197Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
Heartseed Inc.
Phase 1/2
14
Tsukuba, Kawasaki, Matsumoto, Shinagawa-Ku, Shinjuku-ku
2026-01-19
Recruiting
Eli Lilly and Company
Phase 3
150
Abeno, Iruma, Kawasaki, Kofu, Kōriyama, Kumamoto, Nagano, Naka
2026-01-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Nagoya, Kashiwa, Otashi, Sapporo, Himeji, Kobe, Shiwa-gun Yahaba-cho, Kawasaki
2026-01-02
Active, closed
A Clinical Evaluation of AMJ-401
NCT07373353Ischemic Heart Disease (IHD)
Abbott Medical Devices
Not applicable
50
Toyoake, Tokyo, Kitakyushu, Shiwa-gun, Kamakura, Kawasaki, Miyazaki, Sakai
2025-12-17
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
Bristol-Myers Squibb
Phase 3
650
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-12-02
Active, closed
Pfizer
Phase 2
42
Kobe, Kawasaki, Okayama
2025-11-10
Recruiting
Eli Lilly and Company
Phase 3
1,205
Chūō, Fukuyama, Hakodate, Higashiibaraki, Higashiku, Kanazawa, Kawasaki, Kitakyushu
2025-10-31
Recruiting
Pfizer
Phase 2/3
982
Nagoya, Chiba, Kashiwa, Kita-gun, Kawasaki, Yokohama, Suita, Nagaizumi-cho
2025-10-03
Recruiting
Takeda
Phase 3
180
Nagoya, Hirosaki, Chūōku, Shirakawa, Sapporo, Zentsujichó, Kawasaki, Yokohama
2025-10-01
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Kawagoe, Fukuoka, Kawasaki
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Kawasaki, Bunkyo-ku, Koto-ku, Toyoma
2025-09-30
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
Sanofi
Phase 4
35
Kawasaki, Hiroshima, Saitama, Tokyo
2025-09-23
Active, closed
Eli Lilly and Company
Phase 3
800
Fukuoka, Izumo, Kariya, Kawasaki, Minatoku, Miyazaki, Morioka, Saitama
2025-09-15
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Bunkyō City, Funabashi Shi, Hakodate, Kawasaki, Minatoku, Sakura, Yokohama
2025-09-10
Recruiting
Nippon Medical School
Phase 4
500
Chūō, Fukui, Fukuoka, Fukuyama, Hirakata, Kagoshima, Katsuura, Kawasaki
2025-08-01
Recruiting
Bristol-Myers Squibb
Phase 3
586
Inage, Matsudo, Hiroshima, Kita-gun, Kamakura, Kawasaki, Ina, Kashiwazaki
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Ōbu, Narashino, Kawasaki, Tsu, Kurashiki, Hirakata, Kanzaki-gun, Shinjuku
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-07-10
Recruiting
Osaka University
Not applicable
450
Matsudo, Urayasu, Kitakyushu, Kurume, Nishinomiya, Isehara, Kamakura, Kawasaki
2025-06-01
Recruiting
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT07125417Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
OCEAN-SHD Study Group
Phase 4
500
Nagoya, Toyohashi, Matsudo, Kitakyushu, Gifu, Sapporo, Isehara, Kawasaki
2025-05-29
Recruiting
Aveir Leadless Pacemaker Japan PMS
NCT07106788Leadless Pacemaker
Abbott Medical Devices
Observational
304
Nagoya, Kitakyushu, Kawasaki, Sendai, Kurashiki, Hirakata, Osaka, Suita
2025-05-26
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Nagoya, Matsudo, Kawasaki, Yokohama, Habikino, Shinagawa Ku, Fukuoka, Kyoto
2025-05-16
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Fukuoka, Tsu, Kawagoe, Saitama, Hiroshima, Kawasaki, Nagasaki, Saga
2025-03-20
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Kamakura-shi, Sendai, Kurashiki-shi, Saitama, Fuchu-shi, Fukuoka-ken, Kanagawa, Kawasaki
2025-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara
2025-03-16
By invitation
Inari Medical
Observational
100
Chuo, Ōta, Kawasaki, Suita, Asahikawa, Chiba, Daitō, Kanagawa
2025-02-17
Recruiting
Dianthus Therapeutics
Phase 3
256
Niigata, Kawasaki, Tsukuba, Kurashiki, Hirakata, Kawagoe, Ube, Chiba
2025-02-10
Active, closed
Genmab
Phase 3
584
Nagoya, Kurume, Sapporo, Kawasaki, Sendai, Niigata, Okayama, Hidaka
2025-02-07
Recruiting
Novartis Pharmaceuticals
Observational
30
Ōbu, Toyoake, Kurume, Sapporo, Tsukuba, Kawasaki, Yokohama, Tsu
2024-12-19
Active, closed
Pharvaris Netherlands B.V.
Phase 3
81
Kawasaki, Tokyo
2024-12-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Kashiwa, Kitakyushu, Kawasaki, Yokohama, Hirakata, Sakai, Sunto-gun, Shimotsuga-gun
2024-10-21
Recruiting
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Active, closed
Vor Biopharma
Phase 3
191
Nagoya, Sapporo, Kobe, Kawasaki, Yokohama, Sendai, Kashiwazaki-Shi, Ginowan-Shi
2024-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Nagoya, Kashiwa, Ōta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama
2024-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Toyoake, Tōon, Fukuoka, Ōta, Kanazawa, Kawasaki, Yokohama, Natori-shi
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Maebashi, Sapporo, Hizume, Kawasaki, Yokohama, Ehime, Fukuoka, Gifu
2024-03-13
Recruiting
Zephyr Valve Japan Post-Marketing Surveillance
NCT06332885Emphysema, COPD, Severe Emphysema
Pulmonx Corporation
Observational
140
Aichi, Gifu, Kanagawa, Kanazawa, Kawasaki, Mie, Nagasaki, Nagoya
2024-03-12
Active, closed
Study of Tamibarotene in Patients With ADPKD
NCT06289998Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugTamibarotene
Rege Nephro Co., Ltd.
Phase 2
70
Kurume, Sapporo, Kamakura, Kawasaki, Kyoto, Bunkyo-ku, Minato-ku, Shinjukuku
2023-12-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Active, closed
Incyte Corporation
Phase 3
467
Hamamatsu, Kawasaki, Kobe, Kyoto, Minamikoshigaya, Nagasaki, Nagoya, Nankoku
2023-11-29
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
200
Fukuoka, Kawasaki, Miyagi, Tokyo
2023-08-30
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Recruiting
Early Onset Colorectal Cancer Detection
NCT06342401Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I
City of Hope Medical Center
Observational
400
Kawasaki, Mie, Tokyo, Yamagata
2023-04-15
Recruiting
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Active, closed
Sanofi
Phase 3
104
Sapporo, Kagoshima, Kawasaki, Sendai, Fukuoka, Tokyo
2022-05-03
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Kanagawa, Isehara, Kawasaki, Osaka
2022-04-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki
2021-12-13
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
65
Toyoake, Chiba, Kashiwa, Sapporo, Kobe, Kawasaki, Yokohama, Kurashiki
2021-09-23
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Kasugai, Toyoake, Toyota, Sapporo, Kawasaki, Yokohama, Kyoto, Sendai
2021-09-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka
2021-06-18
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Akita, Kōriyama, Nishinomiya, Marugame, Kawasaki, Kochi, Okayama, Izunokuni
2021-04-24
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
Nagoya, Kashiwa-shi, Kawasaki, Osakasayama-shi, Cho-ku, Tokyo
2021-01-11
Active, closed
Pfizer
Phase 3
841
Chiba, Kashiwa, Sapporo, Kanazawa, Kawasaki, Yokohama, Nagoya, Osaka
2020-12-21
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Fukuoka, Kanazawa, Kashihara, Kawasaki, Niigata, Okayama, Osaka, Saitama
2020-12-11
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Kashiwa-shi, Tōon, Sapporo, Kandori, Marugame, Kawasaki, Yokohama, Kyoto
2020-10-27
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Nagoya, Kashiwa-shi, Kawasaki, Osaka, Chuo-ku, Koto-ku
2020-09-15
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Chiba, Nishinomiya, Kawasaki, Sagamihara
2019-10-03
Active, closed
Bristol-Myers Squibb
Phase 3
839
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kawasaki
2019-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Kashiwa, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Sendai, Tomitake, Kashihara
2019-07-24
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Akashi, Kawasaki, Kamigyō-ku
2019-07-11
Recruiting
Cardiac Sarcoidosis Randomized Trial
NCT03593759Cardiac Sarcoidosis, Sarcoidosis
DrugsPrednisolone·Methotrexate·Prednisone
Ottawa Heart Institute Research Corporation
Phase 3
160
Sapporo, Chiba, Fukui, Kawasaki, Nagoya, Osaka, Tokyo
2019-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tōon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fukuoka, Akashi, Kawasaki, Yokohama, Suita, Utsunomiya, Chiba, Kashiwa
2018-11-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Nagoya, Kashiwa, Kitakyushu, Akashi, Kawasaki, Yokohama, Yufu, Fukushima
2018-04-24
Recruiting
UMC Utrecht
Phase 3
20,000
Kawasaki, Yokohama, Minami, Osaka, Tokyo, Wakayama
2016-04-11
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Partner Therapeutics, Inc.
Phase 2
250
Chūōku, Kawasaki, Osaka, Tokyo
2015-01
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Amagasaki, Hamamatsu, Fukuoka, Kagoshima, Kawasaki, Kyoto, Matsuyama, Minato-ku, Tokyo
2014-12-04
Active, closed
Eli Lilly and Company
Phase 3
669
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Sapporo, Nishinomiya, Kawasaki
2014-07-22
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–85 of 85
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 31 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kawasaki

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,504 studies in total at the last sync on 31 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 85 of those studies with a site in Kawasaki.

How many clinical trials are recruiting in Kawasaki?

49 of the 85 studies on this page are recruiting new participants as of the 31 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 32 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kawasaki), 85 studies
PhaseStudiesRecruitingShare
Phase 3492757.6%
Phase 211612.9%
Observational9610.6%
Not applicable627.1%
Phase 2/3444.7%
Phase 4333.5%
Phase 1/2212.4%
Phase 1101.2%

Most active sponsors

Lead sponsors with the most studies (Kawasaki)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC147
Eli Lilly and Company96
Bristol-Myers Squibb65
Novartis Pharmaceuticals54
Pfizer42
Abbott Medical Devices31
Astellas Pharma Global Development, Inc.21
Astria Therapeutics, Inc.20
Genmab21
Janssen Research & Development, LLC22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.